why choose us

First received: March 10, 2023

Clinical Trial: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed/Refractory B-cell Malignancies

Study Type: INTERVENTIONAL


Official Title: A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Malignancy Activity of AC676 in Patients With Relapsed/Refractory B-cell Malign

Brief Summary: This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies.The main goals of the study are to:Identify the recommended dose of AC676 that can be given safely to participantsEvaluate the safety profile of AC676Evaluate the pharmacokinetics of AC676Evaluate the effectiveness of AC676

Read more